Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 11/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25229997 | 0.92 | HDAC6 (0.42) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25277730 | 0.85 | HDAC6 (0.52) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28136805 | 0.77 | HDAC6 (0.49) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25272777 | 0.77 | HDAC6 (0.45) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29050068 | 0.77 | HDAC6 (0.45) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29049990 | 0.76 | HDAC6 (0.41) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29514295 | 0.75 | HDAC6 (0.41) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29514218 | 0.74 | HDAC6 (0.40) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28946897 | 0.73 | HDAC6 (0.43) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2522534 | 0.73 | HDAC6 (0.47) | HDAC6HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4126878-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335057-A | Method for inhibiting casein kinase | 北京原基华毅生物科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115298183-A | Compounds as casein kinase inhibitors | 北京原基华毅生物科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-9956220-B2 | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956220-B2 | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956220-B2 | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170137427-A1 | IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137427-A1 | IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137427-A1 | IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3157925-A1 | IMIDAZO-PYRIDAZNE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015195880-A1 | IMIDAZO-PYRIDAZNE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015195880-A1 | IMIDAZO-PYRIDAZNE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| EP-2556073-B1 | BICYCLIC PYRIDINYL PYRAZOLES | BAYER IP GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8507472-B2 | Bicyclic pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-08-13 | — | — | US | disclosed |
| EP-2556073-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124539-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | PLPBP, PNPO, PIR | HDAC6 1530/4885HDAC3 1541/4885HDAC4 2214/4885 |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | HDAC6 839/4885HDAC3 405/4885HDAC4 324/4885 |
| US-20170137427-A1 | IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS | CSNK1A1, CSNK1G1, CSNK1E | HDAC6 1703/4885HDAC3 1417/4885HDAC4 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.